Clodronate, an inhibitor of the vesicular nucleotide transporter, ameliorates steatohepatitis and acute liver injury
Authors:
Open Access
- 4 March 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-13
Abstract
The vesicular nucleotide transporter (VNUT) is responsible for the vesicular storage and release of ATP from various ATP-secreting cells, and it plays an essential role in purinergic signaling. Although extracellular ATP and its degradation products are known to mediate various inflammatory responses via purinoceptors, whether vesicular ATP release affects steatohepatitis and acute liver injury is far less understood. In the present study, we investigated the effects of clodronate, a potent and selective VNUT inhibitor, on acute and chronic liver inflammation in mice. In a model of methionine/choline-deficient diet-induced non-alcoholic steatohepatitis (NASH), the administration of clodronate reduced hepatic inflammation, fibrosis, and triglyceride accumulation. Clodronate also protected mice against high-fat/high-cholesterol diet-induced steatohepatitis. Moreover, prophylactic administration of clodronate prevented d-galactosamine and lipopolysaccharide-induced acute liver injury by reducing inflammatory cytokines and hepatocellular apoptosis. In vitro, clodronate inhibited glucose-induced vesicular ATP release mediated by VNUT and reduced the intracellular level and secretion of triglycerides in isolated hepatocytes. These results suggest that VNUT-dependent vesicular ATP release plays a crucial role in the recruitment of immune cells, cytokine production, and the aggravation of steatosis in the liver. Pharmacological inhibition of VNUT may provide therapeutic benefits in liver inflammatory disorders, including NASH and acute toxin-induced injury.Keywords
Funding Information
- Japan Society for the Promotion of Science (25253008, 26461383)
This publication has 44 references indexed in Scilit:
- Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responsesPurinergic Signalling, 2013
- Pathological roles of purinergic signaling in the liverJournal of Hepatology, 2012
- P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in miceAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
- Extracellular Nucleotides Inhibit Insulin Receptor Signaling, Stimulate Autophagy and Control Lipoprotein SecretionPLOS ONE, 2012
- A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay developmentCytotechnology, 2011
- Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- The InflammasomesCell, 2010
- Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered miceJournal of Clinical Investigation, 2008
- Adenosine A2A Receptor Occupancy Stimulates Collagen Expression by Hepatic Stellate Cells via Pathways Involving Protein Kinase A, Src, and Extracellular Signal-Regulated Kinases 1/2 Signaling Cascade or p38 Mitogen-Activated Protein Kinase Signaling PathwayMolecular Pharmacology, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005